EMD Serono Appoints CMO
This article was originally published in Scrip
EMD Serono, the US biopharmaceutical business of Merck KGaA., has appointed Joseph Leveque as chief medical officer (CMO). Leveque has over 20 years' experience in strategic leadership roles and medical and clinical programs and has been the medical lead in various biopharmaceutical roles. He joins EMD Serono from Bristol-Myers Squibb where he was head of US medical for oncology. Prior to this, he held medical affairs leadership positions at Onyx Pharmaceutical, Inc., Cephalon and Amgen, Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.